Burjeel Holdings growth accelerates with a 129% Q2 net profit jump, driven by oncology expansion, operational efficiency, and regional service innovation.

Abu Dhabi: Burjeel Holdings PLC has reported exceptional Q2 2025 results, with net profit rising 128.9% to AED 148 million, reflecting strong Burjeel Holdings growth and strategic execution across the MENA region. Revenue climbed 18.7% to AED 1.4 billion, fuelled by a 12% increase in patient footfall, enhanced patient yield, and the ramp-up of new facilities.

Oncology remained a core growth driver, with revenues up 36.7% in Q2. The Group expanded its advanced cancer network by integrating Dubai’s Advanced Care Oncology Center and opening new Burjeel Cancer Institute clinics in Al Ain, Sharjah, and Oman. The UAE’s first dedicated cancer pharmacy also launched, strengthening oncology support infrastructure.

Also Read: Cancer Awareness: FOCP’s Cultural Approach Transforms Stigma into Solidarity

Other notable expansions included the Alkalma mental health platform with four new centres in the UAE and Saudi Arabia, the acquisition of a major Riyadh physiotherapy facility under the PhysioTherabia brand, and the purchase of Medeor Hospital Dubai’s building to convert lease obligations into ownership.

Innovation initiatives featured the DOCKTOUR healthcare logistics joint venture with AD Ports Group, the region’s first Osseointegration Clinic, an Epilepsy Monitoring Unit, and AI-powered diagnostic integration. Research in microgravity aims to transform diabetes care both in space and on Earth.

Also Read: Maple compound shows promise in preventing tooth decay without harmful chemicals

Hospitals contributed 89% of Q2 revenue, rising 17.3%, while Medical Centres delivered 36.8% growth, driven by the ramp-up of over 45 facilities. Burjeel Medical City saw revenue grow 14.7%, with inpatient volumes up and margins improving to 17.6%.

EBITDA surged 59.4% to AED 306 million, with margins expanding to 21.8%. The Group maintained disciplined leverage at 1.8x net debt/EBITDA and reaffirmed its 40–70% dividend payout policy, having distributed AED 170 million for FY2024.

Burjeel Holdings’ focus on specialised care, operational efficiency, and regional expansion positions it for sustained Burjeel Holdings growth, driving shareholder value and strengthening its role as a MENA healthcare leader.